Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
7(78%)
Results Posted
0%(0 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
2
22%
Ph phase_3
2
22%
Ph phase_4
3
33%

Phase Distribution

2

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 3Large-scale testing
2(28.6%)
Phase 4Post-market surveillance
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

7

trials recruiting

Total Trials

9

all time

Status Distribution
Active(7)
Completed(1)
Terminated(1)

Detailed Status

Recruiting5
Active, not recruiting2
Completed1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
7
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (28.6%)
Phase 32 (28.6%)
Phase 43 (42.9%)

Trials by Status

completed111%
recruiting556%
active_not_recruiting222%
terminated111%

Recent Activity

7 active trials
Showing 5 of 9
active_not_recruitingphase_4

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

NCT06752850
recruitingphase_3

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

NCT06716814
recruitingphase_4

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

NCT06940830
recruitingphase_1

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

NCT06579144
terminated

Goal Attainment and Physical Activity in People With Hemophilia A

NCT06530030
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06752850Phase 4

A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis

Active Not Recruiting
NCT06716814Phase 3

Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

Recruiting
NCT06940830Phase 4

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

Recruiting
NCT06579144Phase 1

Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A

Recruiting
NCT06530030

Goal Attainment and Physical Activity in People With Hemophilia A

Terminated
NCT06941870Phase 4

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

Recruiting
NCT05817812Phase 3

A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

Active Not Recruiting
NCT06684314

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan

Recruiting
NCT05042440Phase 1

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9